For over a decade and a half, a persistent enigma has occupied the minds of biomedical researchers: the precise mechanism by which a particular toxin, emanating from a common resident of the human gut microbiome, initiates the cascade of cellular damage that can ultimately lead to colorectal malignancy. This long-standing puzzle has now been decisively unraveled by a collaborative contingent of scientists, shedding light not only on the initial molecular interactions but also illuminating a potential pathway for therapeutic intervention to neutralize the toxin’s harmful influence before it contributes to the progression of cancer.
The groundbreaking revelations stem from an ambitious, multi-institutional endeavor spearheaded by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine. Their seminal work, published in the esteemed journal Nature, conclusively demonstrates that the virulence of this bacterial agent, known scientifically as BFT and secreted by the bacterium Bacteroides fragilis, is contingent upon its ability to first establish a molecular handshake with a specific host protein embedded within the intestinal lining. This protein, identified as claudin-4, acts as a crucial intermediary, granting the toxin access to the cellular machinery it needs to inflict damage. The significant financial backing for this critical research was partially provided by the National Institutes of Health, underscoring the national importance of understanding these intricate biological processes.
Reflecting on the culmination of their efforts, Dr. Cynthia Sears, a distinguished Bloomberg~Kimmel Professor of Cancer Immunotherapy and professor of medicine at Johns Hopkins, expressed profound satisfaction. "The persistent quest to pinpoint this elusive receptor has been a considerable undertaking over many years, making this a truly exhilarating juncture," she stated. Dr. Sears further elaborated on the broader implications of their findings: "A comprehensive grasp of how bacterial toxins exert their effects opens up promising avenues for the development of novel diagnostic tools and therapeutic strategies aimed at combating associated pathologies, ranging from acute diarrheal diseases and the insidious development of colorectal cancer to potentially life-threatening bloodstream infections."
The ramifications of this discovery are already catalyzing the design of an innovative strategy intended to counteract the toxin’s detrimental actions. In preclinical investigations utilizing animal models, researchers have successfully engineered a molecular decoy. This ingeniously designed construct effectively intercepted the BFT toxin, preventing it from engaging with and subsequently compromising the integrity of the colon’s cellular defenses.
Bacteroides fragilis is a prevalent inhabitant of the human gastrointestinal tract, present in as many as one-fifth of healthy individuals. However, certain specific strains possess the capacity to induce chronic inflammation within the colon and actively foster an environment conducive to tumor proliferation. Prior investigations originating from Dr. Sears’ laboratory had already established that BFT contributes to this chronic inflammation by cleaving E-cadherin, a vital protein responsible for maintaining the structural integrity and protective barrier function of the colonic epithelium. That earlier research, also published in Nature Medicine, had provided compelling evidence linking the toxin’s activity directly to the initiation and progression of colon tumors.
Despite these significant advancements, a pivotal question remained stubbornly unanswered. BFT did not exhibit a direct binding affinity for E-cadherin, leading scientists to hypothesize the existence of an intermediary molecule that facilitated the toxin’s initial engagement with its ultimate target.
To unravel this missing link, a comprehensive, genome-wide CRISPR screening endeavor was initiated, spearheaded by Maxwell White, an M.D./Ph.D. candidate within the Sears laboratory. This ambitious project was conducted in close collaboration with the research group of Professor Matthew Waldor at Harvard Medical School, a renowned expert in infectious diseases.
The experimental approach involved systematically deactivating individual genes within cultured colon epithelial cells. By observing the consequences of each gene inactivation, the researchers aimed to identify which specific genes were indispensable for the toxin’s destructive functionality. Among the multitude of genetic targets, one protein emerged with striking prominence: claudin-4. When the expression of claudin-4 was experimentally abrogated, the BFT toxin proved incapable of attaching to the cells, thereby leaving the critical E-cadherin protein undisturbed and its protective function intact.
"The process of optimizing the assay and validating our experimental design required considerable perseverance," recounted White. "However, once we were able to execute the screen, claudin-4 stood out as an unequivocally clear and dominant hit. That was an exceptionally gratifying moment." The researchers themselves expressed surprise at this particular finding. Dr. Sears noted that a significant portion of the scientific community had anticipated the receptor to be a protein involved in cellular signaling pathways, such as a G-protein coupled receptor. Instead, claudin-4 belongs to a distinct and less expected category of proteins. Furthermore, an extensive review of existing scientific literature failed to identify any other known toxin that operates through a comparable mechanism. The vast majority of toxins that function as proteases, meaning they break down proteins, typically bind directly to their substrate molecules rather than relying on a separate receptor for initial attachment.
To unequivocally confirm the newly identified molecular interaction, the Johns Hopkins researchers forged a crucial partnership with leading structural biologists F. Xavier Gomis-Rüth and Ulrich Eckhard at the prestigious Molecular Biology Institute of Barcelona.
Employing sophisticated biophysical techniques, White, in conjunction with his counterparts in Barcelona, conducted a series of laboratory experiments. These investigations conclusively demonstrated that BFT and claudin-4 form a remarkably stable, one-to-one molecular complex. This physical evidence provided the first direct confirmation that the toxin indeed attaches to the claudin-4 receptor prior to initiating its damaging effects on the colon cells.
Subsequently, to validate these findings within a living biological system, the research team collaborated with the laboratory of Professor Min Dong at Harvard Medical School. Working alongside Kang Wang and his colleagues, they meticulously examined the behavior of the BFT toxin in meticulously designed mouse models of intestinal disease.
The team ingeniously devised a soluble variant of the claudin-4 protein, engineered to function as a molecular decoy. This decoy molecule was designed to present specific structural elements of the claudin-4 receptor that are normally recognized and bound by the BFT toxin. The strategic intent was for the BFT toxin to preferentially bind to these decoy proteins circulating in the system, thereby diverting it away from its intended target on the surface of colon cells. This innovative therapeutic approach proved highly successful in protecting the laboratory mice from the damaging effects of BFT-induced colon injury.
"This fundamental approach holds significant promise for further development," remarked White. "It can be adapted and refined through the utilization of small molecules or other biological agents possessing more favorable pharmacological characteristics." The research team is currently engaged in ongoing investigations to determine which specific therapeutic modalities would be most efficacious in neutralizing the BFT toxin.
Despite the significant progress in identifying the receptor and confirming its tight binding with BFT, a crucial challenge persists. The precise three-dimensional atomic structure depicting the exact manner in which the toxin and claudin-4 interlock remains elusive. Even advanced artificial intelligence modeling tools, including the sophisticated AlphaFold system, have thus far been unable to fully resolve this intricate molecular interaction.
The collaborative effort involved a broad spectrum of researchers, with additional contributing authors to the Nature publication including Jason Chen, Shaoguang Wu, Abby L. Geis, and Jessica Queen from Johns Hopkins, as well as Hailong Zhang, Karthik Hullahalli, and Jie Zhang from Harvard Medical School.
The research received vital financial support from several key organizations, including the Bloomberg~Kimmel Institute for Cancer Immunotherapy, Janssen Research and Development, Cancer Research UK, and the National Institutes of Health, which provided grant funding under numbers R01 AI042347, R01 NS080833, R01 NS117626, R01 AI170835, and R01 AI189789. The Howard Hughes Medical Institute also contributed essential resources to this critical scientific undertaking.
Dr. Sears has disclosed a financial relationship with UpToDate, from which she receives royalties for writing and reviewing content. This arrangement is managed by The Johns Hopkins University in strict accordance with its established policies for managing potential conflicts of interest.
About the Author
